Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials

Brian R Dulin; Steven J Haas; William T Abraham; Henry Krum

doi:10.1016/j.amjcard.2004.11.052

Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials

Am J Cardiol. 2005 Apr 1;95(7):896-8. doi: 10.1016/j.amjcard.2004.11.052.

Authors

Brian R Dulin¹, Steven J Haas, William T Abraham, Henry Krum

Affiliation

¹ NHMRC Centre of Clinical Research Excellence in Therapeutics, Departments of Epidemiology and Preventive Medicine and Medicine, Monash University, Alfred Hospital, Melbourne, Australia. brian.dulin@aya.yale.edu

PMID: 15781028
DOI: 10.1016/j.amjcard.2004.11.052

Abstract

A meta-analysis of all-cause mortality data involving elderly and non-elderly chronic heart failure patients from 5 completed beta-blocker trials revealed that elderly and non-elderly chronic heart failure patients derived considerable prognostic benefit from beta-blocker therapy without a statistically significant difference in mortality reduction between the 2 groups.

Publication types

Meta-Analysis

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Age Factors
Aged
Heart Failure / drug therapy*
Heart Failure / mortality
Humans
Middle Aged
Systole
Treatment Outcome

Substances

Adrenergic beta-Antagonists